Inhibition of the DDR1 enzyme with a newly identified small molecule compound can prevent renal tissue scarring and renal function loss in a mouse model of Alport syndrome, a study shows. The study, “DNA-encoded library-derived DDR1 inhibitor prevents fibrosis and renal function loss in a genetic mouse…
A case study of Alport syndrome will be the subject of an oral presentation and discussion at the 96th annual meeting of the American Academy of Optometry (AAO), Oct. 11-14 in Chicago. Titled “A Mutation in the Basement: Case Discussion of Alport Syndrome,” the case study will be…
Regulus Therapeutics has completed dosing of its Alport syndrome drug candidate RG-012 in a Phase 1 trial testing several ascending doses of the treatment in healthy volunteers. The treatment was found safe and well-tolerated, and no serious adverse events were seen during the trial. The company also announced it…
The Alport Syndrome Foundation (ASF) welcomes all who are interested to take part in its 2nd Annual Virtual Walk, a fundraising event to help fight Alport syndrome. Virtual walk participants can walk anytime, anywhere, and with anyone. There’s no cost to participate. Anyone who wants to take part can register here for…
Get regular updates to your inbox.